Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CADL vs ENTA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CADL Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–3 Matrix Metrics)

CADL Overall Winner 6-Pillar Tally: CADL 3 – 2 ENTA (1 Tie) Matrix Metrics: CADL 7 – 3 ENTA

As of Nov 16, 2026, Candel Therapeutics, Inc. (CADL) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CADL carries a Unified Composite Score of 46.0/100 (HOLD) at $5.81 (43.5x Forward P/E, 0.0% operating margin), whereas ENTA carries 46.2/100 (HOLD) at $10.67 (44.0x Forward P/E, -90.0% operating margin).

  • Technical & Structure Timing Caution: CADL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CADL vs ENTA
CADL NASDAQ Head-to-Head Winner
Candel Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$5.81
-6.29% 1D
Market Cap $486.4M
TTM Revenue $31,000
Forward P/E 43.5x
Beta / 30D Vol 2.12β · 125% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 33.0 Fund 55.0 Flow 70.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -14.8%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $8.33 · SMA50: $9.62
ENTA NASDAQ
Enanta Pharmaceuticals, Inc
Pharmaceutical Preparations
$10.67
-2.91% 1D
Market Cap $320.1M
TTM Revenue $65M
Forward P/E 44.0x
Beta / 30D Vol 0.88β · 58% Vol
Unified Composite Score
46.2 / 100 HOLD
Tech 53.0 Fund 54.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $11.18 · SMA50: $11.88

6-Pillar Scorecard Institutional Category Breakdown (CADL 3 – 2 ENTA)

Columns: Metric · CADL · ENTA
1. Valuation Multiples CADL
Forward P/E 43.5x 44.0x
Trailing P/E 43.5x 44.0x
PEG Ratio N/M N/M
EV / Revenue N/M 5.2x
2. Growth & Scale CADL
Revenue Growth (YoY) +0.0% -21.6%
Earnings Growth (YoY) +0.0% -66.2%
TTM Revenue (USD) $31,000 $65M
Market Cap $486.4M $320.1M
3. Profitability & Quality CADL
Gross Margin N/A 100.0%
Operating Margin 0.0% -90.0%
Net Profit Margin 0.0% -96.9%
Return on Equity (ROE) -93.7% -70.1%
4. Balance Sheet & Cash Flow ENTA
Cash Generation (TTM) -$57M -$37M
Cash Flow Margin N/A -56.6%
Net Cash / Leverage $152M Net Cash $22M Net Debt (0.55x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTA
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 115.4% (24th %ile) 78.7% (11th %ile)
Put/Call OI Skew 0.50x (Call-Skewed) 0.31x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CADL (7) vs ENTA (3)
Institutional Metric CADL ENTA Criterion Row Edge
Market Capitalization
Scale
$486.4M $320.1M Larger Scale CADL
Trailing P/E Ratio
Valuation
43.5x 44.0x Lower Multiple CADL
Forward P/E Ratio
Valuation
43.5x 44.0x Lower Multiple CADL
Revenue Growth (YoY)
Growth
+0.0% -21.6% Higher Growth CADL
Operating Margin (TTM)
Profitability
0.0% -90.0% Higher Margin CADL
Net Profit Margin
Profitability
0.0% -96.9% Higher Margin CADL
Return on Equity (ROE)
Capital Efficiency
-93.7% -70.1% Higher ROE ENTA
52-Week Range Position
Momentum
15% ($4–$14) 9% ($10–$17) Stronger Trend CADL
Beta / 30D Volatility
Risk Regime
2.12β · 125% Vol 0.88β · 58% Vol Lower Realized Risk ENTA
Unified Institutional Score
Composite Signal
46.0 / 100 (HOLD) 46.2 / 100 (HOLD) Higher Composite ENTA
Trailing 12M Revenue (USD)
Operating Scale
$31,000 $65M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 5.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$57M ($152M Net Cash) -$37M ($22M Net Debt (0.55x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENTA +25.19 pp
CADL: -29.06% · ENTA: -3.87%
3M Horizon ENTA +32.01 pp
CADL: -51.78% · ENTA: -19.77%
6M Horizon ENTA +5.79 pp
CADL: -26.46% · ENTA: -20.67%
1Y Horizon CADL +34.99 pp
CADL: +26.03% · ENTA: -8.96%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CADL Revenue ENTA Revenue CADL Op. Margin ENTA Op. Margin Margin Leader
FY2018 N/A $210M N/A 42.7% ENTA
FY2019 N/A $210M N/A 17.9% ENTA
FY2020 $0M $120M -11048.0% -34.0% ENTA
FY2021 $0M $100M -20580.8% -112.9% ENTA
FY2022 $0M $90M -27777.6% -143.7% ENTA
FY2023 N/A $80M N/A -173.2% ENTA
FY2024 N/A $70M N/A -179.9% ENTA
FY2025 N/A $70M N/A -130.7% ENTA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CADL BREAKDOWN
98d in phase · OBV DISTRIBUTION
Current IV 115.4%
IV Percentile 24th %ile
Put/Call OI Skew 0.50x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact CADL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTA BREAKDOWN
95d in phase · OBV NEUTRAL
Current IV 78.7%
IV Percentile 11th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact ENTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CADL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $486.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $320.1M market capitalization and -90.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CADL vs ENTA Key Questions & Quantitative Answers

As of Nov 16, 2026, Candel Therapeutics, Inc. (CADL) is the stronger overall head-to-head candidate over Enanta Pharmaceuticals, Inc (ENTA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CADL carries a Unified Composite Score of 46.0/100 (HOLD) at $5.81 (43.5x Forward P/E, 0.0% operating margin), whereas ENTA carries 46.2/100 (HOLD) at $10.67 (44.0x Forward P/E, -90.0% operating margin). Technical & Structure Timing Caution: CADL is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 30.7); meanwhile ENTA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CADL leads the Growth & Scale pillar: CADL posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $31,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with ENTA at -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CADL cumulative revenue shifted N/A while ENTA shifted -66.7%. In operating R&D and SG&A reinvestment, CADL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTA.

CADL screens cheaper on headline valuation multiples. CADL trades at 43.5x Forward P/E, 43.5x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.2x EV/Revenue (-56.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CADL (-93.7% ROE) versus ENTA (-70.1% ROE) capital efficiency.

In options market volatility and institutional positioning, CADL carries 115.4% implied volatility (24th %ile, Compressed (<25th %ile)), a 0.50x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.12β · 125% Vol realized risk). By comparison, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.88β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.